Business Context and Reporting Period
This Form 8-K, filed on August 16, 2005, reports events occurring on August 10, 2005. Atricure, Inc. consummated the acquisition of Enable Medical Corporation ("Enable") immediately following the closing of its initial public offering. Enable manufactured Isolator handpieces, an essential component of Atricure's bipolar ablation system, and operated two business units: Surgical Products and Design and Manufacturing.
Key Financial Metrics
Financial data provided in the filing pertains to Enable Medical Corporation prior to the merger:
- Revenue (Enable, FY 2004): $6.9 million
- Net Income (Enable, FY 2004): $0.8 million
- Pre-Closing Dividend: Enable paid a cash dividend of $0.5 million to shareholders immediately prior to the merger closing.
- Workforce: Enable employed 51 people as of May 31, 2005.
The filing text does not provide specific revenue, profit, cash flow, or debt metrics for Atricure, Inc. for the current period, nor does it detail the total purchase price of the acquisition in this summary text.
Material Changes and Transaction Terms
The primary material change is the full acquisition of Enable. The transaction includes contingent payment provisions regarding the sale of Enable assets unrelated to the Atricure bipolar ablation system:
- Sales before Dec 31, 2005: Atricure and former Enable shareholders split proceeds 50/50.
- Sales after Dec 31, 2005 (within 3 years): Atricure pays former shareholders 50% of proceeds exceeding $1 million, capped at a maximum payment of $2 million.
Management Commentary, Risks, and Related Party Transactions
Related Party Transaction: Three members of Atricure's board of directors held approximately 63% of Enable's outstanding common stock. Consequently, these directors received the majority of the consideration paid to acquire Enable. One of these directors, Michael Hooven (Atricure's Chief Technology Officer), was also a director and officer of Enable.
Operational Synergy: The acquisition secures the manufacturing of Isolator handpieces and integrates Enable's radio-frequency technology portfolio and contract manufacturing capabilities.
Investor Verification Checklist
- Verify the total consideration paid for Enable, as the specific purchase price is not explicitly stated in the summary text.
- Review the "Unaudited Pro Forma Condensed Combined Financial Information" (Exhibit 99.3) to understand the combined financial impact of the merger.
- Assess the valuation of Enable's non-core assets subject to the contingent payment clauses.
- Confirm the extent of the related party transaction impact on the board's independence and financial interests.